Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Total Current Liabilities (2021 - 2025)

Historic Total Current Liabilities for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $28.9 million.

  • Verrica Pharmaceuticals' Total Current Liabilities rose 3748.69% to $28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year increase of 3748.69%. This contributed to the annual value of $29.0 million for FY2024, which is 7041.82% up from last year.
  • As of Q3 2025, Verrica Pharmaceuticals' Total Current Liabilities stood at $28.9 million, which was up 3748.69% from $29.2 million recorded in Q2 2025.
  • Verrica Pharmaceuticals' Total Current Liabilities' 5-year high stood at $46.4 million during Q3 2021, with a 5-year trough of $2.6 million in Q1 2023.
  • For the 5-year period, Verrica Pharmaceuticals' Total Current Liabilities averaged around $26.0 million, with its median value being $28.9 million (2025).
  • Per our database at Business Quant, Verrica Pharmaceuticals' Total Current Liabilities crashed by 9410.04% in 2023 and then soared by 63269.01% in 2024.
  • Verrica Pharmaceuticals' Total Current Liabilities (Quarter) stood at $46.1 million in 2021, then tumbled by 92.49% to $3.5 million in 2022, then surged by 392.17% to $17.0 million in 2023, then soared by 70.42% to $29.0 million in 2024, then fell by 0.36% to $28.9 million in 2025.
  • Its Total Current Liabilities stands at $28.9 million for Q3 2025, versus $29.2 million for Q2 2025 and $29.4 million for Q1 2025.